Back to Search Start Over

Correlation of limited-early-response status with 12-month CST, BVA, and machine learning-quantified retinal fluid in diabetic macular oedema in routine clinical practice.

Authors :
Sastry RC
Perkins SW
Kalur A
Singh RP
Source :
Eye (London, England) [Eye (Lond)] 2024 Oct; Vol. 38 (14), pp. 2805-2812. Date of Electronic Publication: 2024 Jun 18.
Publication Year :
2024

Abstract

Background/objectives: Anti-VEGF treatment response in DMO has been measured by changes in the central subfield thickness (CST) and best visual acuity (BVA) outcomes at 3 months after initial treatment, termed early or limited early response (ER/LER). This study correlates LER with 12-month BVA, CST, and retinal fluid volumes quantified by a machine learning algorithm on optical coherence tomography (OCT).<br />Subjects/methods: The study included treatment naïve DMO patients ≥ 18 years with OCT scans at baseline (M0), M3, M6, and M12. The 220 patients were categorized as limited early responders (LER) if they had ≤ 10% CST reduction and/or < 5 ETDRS letter gain at M3. BVA, CST, and subretinal (SRF), intraretinal (IRF), and total retinal (TRF) fluid volumes quantified by a machine learning algorithm were compared between groups and across time.<br />Results: At M12, the anatomic LER (aLER), defined solely by CST, had significantly worse BVA and CST versus the anatomic ER (aER) group (p < 0.001). Retinal fluid M12 outcomes did not significantly vary between all LER and ER groups. No significant BVA, CST, TRF, and IRF variance across time for LER was found (p > 0.1).<br />Conclusions: BVA and CST M12 outcomes vary by aLER/aER status indicating that CST may be a strong predictor of treatment outcomes, while retinal fluid volumes were not predicted by LER status.<br /> (© 2024. The Author(s).)

Details

Language :
English
ISSN :
1476-5454
Volume :
38
Issue :
14
Database :
MEDLINE
Journal :
Eye (London, England)
Publication Type :
Academic Journal
Accession number :
38890549
Full Text :
https://doi.org/10.1038/s41433-024-03172-4